Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:201-210
doi: 10.1161/hq0202.102318
doi: 10.1161/hq0202.102318
© 2002 American Heart Association, Inc.
Brief Reviews |
Female Hormones and Thrombosis
From the Departments of Clinical Epidemiology (F.R.R., J.P.V.), Hematology (F.R.R.), and Obstetrics, Gynecology and Reproductive Medicine (F.M.H.),. Leiden University Medical Center, Leiden, the Netherlands.
Correspondence to Prof Dr F.R. Rosendaal, Clinical Epidemiology, LUMC, PO Box 9600, NL-2300 RC Leiden, Netherlands. E-mail f.r.rosendaal{at}lumc.nl
Exogenous hormones are used by more than a hundred million women worldwide as oral contraceptives or for postmenopausal hormone replacement. Oral contraceptives increase the risk of venous thrombosis, of myocardial infarction, and of stroke. The risk is highest during the first year of use. The venous thrombotic risk of oral contraceptives is high among women with coagulation abnormalities and with so-called third-generation contraceptives (containing desogestrel or gestodene). The risk of myocardial infarction does not appear to depend on coagulation abnormalities or the type of oral contraceptive. Hormone replacement therapy increases the risk of venous thrombosis. This risk is also highest in the first year of use and among women with coagulation abnormalities. The risk becomes very high in women with a previous venous thrombosis. Randomized trials have not confirmed a beneficial effect of postmenopausal hormones on the occurrence of myocardial infarction.
Key Words: venous thrombosis • myocardial infarction • stroke • oral contraceptives • hormone replacement therapy
This article has been cited by other articles:
 |
|
 |
|
  M. Canonico, E. Bouaziz, L. Carcaillon, C. Verstuyft, A. Guiochon-Mantel, L. Becquemont, P.-Y. Scarabin, and for the Estrogen Thromboembolism Risk (ESTHER) Stu Synergism between Oral Estrogen Therapy and Cytochrome P450 3A5*1 Allele on the Risk of Venous Thromboembolism among Postmenopausal Women J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3082 - 3087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. F. Tapson Acute Pulmonary Embolism N. Engl. J. Med., March 6, 2008; 358(10): 1037 - 1052. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Migliacci, C. Becattini, R. Pesavento, G. Davi, M. C. Vedovati, G. Guglielmini, E. Falcinelli, G. Ciabattoni, F. Dalla Valle, P. Prandoni, et al. Endothelial dysfunction in patients with spontaneous venous thromboembolism Haematologica, June 1, 2007; 92(6): 812 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ramot and A. Nyska Drug-Induced Thrombosis--Experimental, Clinical, and Mechanistic Considerations Toxicol Pathol, February 1, 2007; 35(2): 208 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rayner, Y.-X. Chen, B. Hibbert, D. White, H. Miller, E. H. Postel, and E. R. O'Brien NM23-H2, an estrogen receptor beta-associated protein, shows diminished expression with progression of atherosclerosis Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R743 - R750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mira, C. Morata, A. Vaya, F. Ferrando, T. Contreras, and J. Aznar Is yasmin as safe as other contraceptive pills? Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 378 - 379. [PDF]
|
|
|
|
 |
|
 J. D. Curb, R. L. Prentice, P. F. Bray, R. D. Langer, L. Van Horn, V. M. Barnabei, M. J. Bloch, M. G. Cyr, M. Gass, L. Lepine, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med, April 10, 2006; 166(7): 772 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Straczek, E. Oger, M. B. Yon de Jonage-Canonico, G. Plu-Bureau, J. Conard, G. Meyer, M. Alhenc-Gelas, H. Levesque, N. Trillot, M.-T. Barrellier, et al. Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration Circulation, November 29, 2005; 112(22): 3495 - 3500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yoshizawa, G. E. Kissling, J. A. Johnson, N. P. Clayton, N. D. Flagler, and A. Nyska Chemical-Induced Atrial Thrombosis in NTP Rodent Studies Toxicol Pathol, August 1, 2005; 33(5): 517 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. T. van der Schouw and D. E. Grobbee Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy Eur. Heart J., July 2, 2005; 26(14): 1358 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Haines and E. A. Nutescu Current and emerging treatment options for venous thrombosis: A case discussion Am. J. Health Syst. Pharm., March 15, 2005; 62(6): 593 - 605. [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Rosendaal Venous Thrombosis: The Role of Genes, Environment, and Behavior Hematology, January 1, 2005; 2005(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. V. Gomes and S. R. Deitcher Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review Arch Intern Med, October 11, 2004; 164(18): 1965 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cushman, L. H. Kuller, R. Prentice, R. J. Rodabough, B. M. Psaty, R. S. Stafford, S. Sidney, F. R. Rosendaal, and for the Women's Health Initiative Investigators Estrogen Plus Progestin and Risk of Venous Thrombosis JAMA, October 6, 2004; 292(13): 1573 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Legro, E. Myers, and for the Reproductive Medicine Network Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum. Reprod., August 1, 2004; 19(8): 1697 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hultgren, P. Olofsson, and E. Wahlberg Reproductive History in Women with Lower Limb Ischemia Angiology, July 1, 2004; 55(4): 373 - 383. [Abstract] [PDF]
|
|
|
|
|
|
P. Alexandersen, J. Haarbo, P. Zandberg, J. Jespersen, S. O. Skouby, and C. Christiansen Lack of difference among progestins on the anti-atherogenic effect of ethinyl estradiol: a rabbit study Hum. Reprod., July 1, 2003; 18(7): 1395 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Reiner, S. R. Heckbert, H. L. Vos, R. A. S. Ariens, R. N. Lemaitre, N. L. Smith, T. Lumley, T. D. Rea, L. A. Hindorff, G. D. Schellenbaum, et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction Blood, July 1, 2003; 102(1): 25 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Rapp, M. A. Espeland, S. A. Shumaker, V. W. Henderson, R. L. Brunner, J. E. Manson, M. L. S. Gass, M. L. Stefanick, D. S. Lane, J. Hays, et al. Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial JAMA, May 28, 2003; 289(20): 2663 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R Deitcher and M. P. Gomes Hypercoagulable state testing and malignancy screening following venous thromboembolic events Vascular Medicine, February 1, 2003; 8(1): 33 - 46. [Abstract] [PDF]
|
|
|
|
 |
|
 G. L. Hoetzer, B. L. Stauffer, J. J. Greiner, Y. Casas, D. T. Smith, and C. A. DeSouza Influence of oral contraceptive use on endothelial t-PA release in healthy premenopausal women Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E90 - E95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Bauer Hormone Replacement Therapy and the Factor V Leiden Mutation Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 879 - 880. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Bauer, F. R. Rosendaal, and J. A. Heit Hypercoagulability: Too Many Tests, Too Much Conflicting Data Hematology, January 1, 2002; 2002(1): 353 - 368. [Abstract] [Full Text]
|
|